Tag Archives: innovation

#AI – Diagnosis on demand – and disappointment

Posted on November 3, 2018 by Julia Manning

Thursday evening’s Horizon, subtitled ‘The Computer will see you now’ is the latest in a lengthening line of programmes and books that purport to critique today’s medical zeitgeist: Artificial Intelligence in healthcare. It was entertaining. I understand. Who would have … Continue reading →

Posted in Information, Policy, Technology | Tagged , , , , , , | Leave a comment

Baby Boomer women and tech – new report

Posted on May 26, 2016 by 2020healthGuest

Guest blog by Kathy Mason Associate, 2020health Elder care with technology appeals most to Baby Boomer women Two thirds of 55-75 year olds would be interested in using technology to help their parents as they get older. Help with medication, memory, … Continue reading →

Posted in Elderly, Emerging technologies, Health and Wellbeing, Healthcare, Innovation, Preventative healthcare, Self-care, Technology | Tagged , , , , , , | Leave a comment

Are pharmaceutical mega-mergers in the public interest?

Posted on May 2, 2014 by Barbara Arzymanow

The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development –  R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading →

Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Medical advisory body “NICE” should not spend too much time valuing drugs.

Posted on April 14, 2014 by Barbara Arzymanow

The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading →

Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.

Posted on December 4, 2013 by Barbara Arzymanow

The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading →

Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban | Tagged , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease

Posted on October 16, 2013 by Barbara Arzymanow

Guest blog post from Barbara Arzymanow, Independent Healthcare Consultant  Sir David Jack (1924-2011), one of history’s greatest pharmaceutical R&D directors under whom many important drugs were discovered, once told me that neither governments nor companies should overrule senior R&D management. … Continue reading →

Posted in Business, Drugs, Innovation | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Pharmaceutical Industry- Innovation is the only way forward.

Posted on August 14, 2013 by Barbara Arzymanow

The headline news from the Health and Social Care Information Centre (HSCIC) states that more than 1 billion prescription items were dispensed by community pharmacies in England for the first time in 2012. However, we must not be complacent about the serious … Continue reading →

Posted in Uncategorized | Tagged , , , , , , , , | 1 Comment

Guest Blogspot: Waiting for Decisions on UK Pharmaceutical Pricing

Posted on April 4, 2013 by Barbara Arzymanow

Little has been heard over how confidential talks between the Government and the pharmaceutical industry are progressing towards the goal of having a new, voluntary UK drug pricing system in place in 2014. In the eyes of the pharmaceutical companies … Continue reading →

Posted in Andrew Lansley, Business, Children, Commissioning, David Cameron, Department of Health, Drugs, Emerging technologies, equality, Health and Wellbeing, Innovation, Jeremy Hunt, Uncategorized, Wellbeing | Tagged , , , , , , , , , , , , | 1 Comment

Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.

Posted on September 20, 2012 by Barbara Arzymanow

David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading →

Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: The Pharmaceutical Industry – Friend or Foe?

Posted on July 18, 2012 by Barbara Arzymanow

Recent months have seen publicity over examples of disgraceful behaviour by pharmaceutical companies. The question arises as to whether the failings have been rare and exceptional or whether they are indicative of generally low moral standards in the industry. Pharmaceutical … Continue reading →

Posted in Alcohol, Business, Drugs, Finance, GPs, Information, NHS, Obesity, Research | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment